leuprolide acetate for depot suspension / Generic mfg. - LARVOL DELTA

Preservation of gonadal function following chemotherapy protocols with acvd and acvd-BV in adults diagnosed with advanced-stage Hodgkin lymphoma: A single center experience. (ASH 2025) - "ACVD (Adriamycin 25 mg/m², Cyclophosphamide 400 mg/m², Vinblastine 6 mg/m² (max 10 mg) and Dacarbazine 375 mg/m²) is a modified chemotherapy regimen from ABVD given IV on day 1 and day 15 and repeated every 28 days for 6 cycles, replacing bleomycin with low dose cyclophosphamide to further optimize efficacy and reduce pulmonary and gonadal toxicity. Brentuximab vedotin is added to ACVD (ACVD-BV) in those cases of positive PET following 2 cycles of ACVD...Sperm banking was performed for 18/34 (53%) males before starting chemotherapy, and only 3/22 (13.617%) females received leuprorelin (GnRH agonist) during the chemotherapy... This study shows a favorable advantage of ACVD /ACVD-BV chemotherapy in treating advanced-stage HL where majority of cases gained their gonadal functions. However, limitations include retrospective design, missing baseline gonadal function evaluation, particularly semen analyses, and inconsistent hormone level documentation...."

Clinical • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Fertility preservation in AYA oncology: Provider knowledge gaps, counseling practices, and barriers to care (ASH 2025) - "While 58% felt knowledgeable about leuprolide for ovariansuppression therapy, vignette responses suggested potential overuse inconsistent with nationalguidelines.Among participants, 77% consistently asked about fertility importance, 61% incorporated fertility goalsinto treatment planning, 58% discussed treatment-related infertility risks, 62% made referrals whenappropriate, 43% provided educational materials, and 73% documented FP conversations in the EMR.Commonly cited barriers included patient acuity (58%), affordability (27%), provider time constraints(27%), logistical challenges (23%), and patient reluctance to discuss FP (23%)... Providers reported moderate comfort with FP counseling and referrals yet demonstratedlimited knowledge on several FP procedures. Knowledge was particularly low for less common options,such as OTC. Most had little to no formal training, acquiring knowledge primarily through literature andlectures, highlighting the need for more interactive,..."

CNS Disorders • Depression • Hematological Malignancies • Infertility • Mood Disorders • Psychiatry • Sexual Disorders

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints. (PubMed, J Urol) - P3 | "Secondary endpoint results support enzalutamide monotherapy as a potential option to improve efficacy and preserve sexual health vs leuprolide alone for patients with high-risk biochemical recurrence. NCT02319837."

Journal • Monotherapy • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial. (PubMed, J Urol) - P3 | "Combined with the primary findings from EMBARK, data from non-key secondary efficacy endpoints strengthen support for enzalutamide combination as a new standard of care for patients with high-risk BCR. NCT02319837."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) - P2 | N=25 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2027 ➔ Nov 2028 | Trial primary completion date: Jan 2027 ➔ Nov 2028

Enrollment closed • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Value of contrast-enhanced ultrasound in evaluating blood flow perfusion changes in adenomyosis patients treated with HIFU combined with leuprorelin. (PubMed, Curr Probl Surg) - No abstract available

Journal • Endometriosis • Women's Health

The Role of Hormones in Postpartum Mood Disorders (clinicaltrials.gov) - P2 | N=74 | Completed | Sponsor: National Institute of Mental Health (NIMH) | N=54 ➔ 74

Enrollment change • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

Unresectable Desmoplastic Small Round Cell Tumor: A Case Report and Review of the Literature. (PubMed, Case Rep Oncol) - "We report the case of a 38-year-old male with unresectable intra-abdominal DSRCT treated with the VAC-IE regimen (vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide) as first-line therapy...As second-line therapy, he received gemcitabine and docetaxel...Alternative regimens include temozolomide plus irinotecan or gemcitabine plus doxorubicin. In patients with androgen receptor positivity, hormonal blockade with leuprolide and bicalutamide may be a therapeutic option, particularly in frail patients...DSRCT is a challenging and aggressive malignancy requiring a multidisciplinary and individualized approach. The combination of systemic therapy and local control measures remains critical for improving patient outcomes."

Journal • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • AR • EWSR1 • WT1

A randomized phase II study comparing monthly versus 3-monthly GnRH agonist for ovarian function suppression in premenopausal patients with HR-positive breast cancer: study design and rationale (SABCS 2025) - "Background: The SOFT and TEXT trials have shown substantial survival benefit from adding ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa) to aromatase inhibitors (AI), compared with tamoxifen alone in premenopausal patients with hormone receptor (HR)-positive breast cancer...Patients will be stratified by prior chemotherapy (yes vs. no) and randomly assigned in a 1:1 ratio to receive either leuprolide at a dose of 22.5 mg every 12 weeks (Cohort A) or leuprolide at a dose of 7.5 mg every 4 weeks (Cohort B), both administered as a single intramuscular injection, in combination with an AI... OFS management remains a major challenge for oncologists worldwide, with limited evidence to guide optimal GnRHa dosing schedules. This study will generate prospective data comparing OFS using monthly versus 3-monthly GnRHa in combination with adjuvant endocrine therapy, addressing an important gap in clinical practice. The findings may contribute..."

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

NRG-BR009: A phase III trial evaluating addition of adjuvant chemotherapy to Ovarian Function Suppression + Endocrine Therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer and recurrence score ≤25 (OFSET) (SABCS 2025) - P3 | "ET is an aromatase inhibitor (AI) per physician discretion; or tamoxifen if AI is not tolerated or if OFS is incomplete. Among 148 pts with OFS data available, 79 (53.4%) were prescribed goserelin and 69 (46.6%) leuprolide. A monthly dosing schedule was prescribed for 86.1% of pts receiving goserelin and 73.5% of those receiving leuprolide; the remaining received a 3-monthly schedule.NCT05879926 Support: U10 CA180868, -80822, UG1 CA189867, U24 CA196067"

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

When Therapy Leaves a Mark: A Case of Ribociclib-Induced Vitiligo Reversed with Abemaciclib (SABCS 2025) - "She underwent adjuvant therapy with Lupron and tamoxifen but self-discontinued treatment after three years...Treatment was initiated with ribociclib, letrozole, and zoladex; genomic profiling (NGS) showed no targetable mutations.After two years of therapy, the patient developed depigmented patches localized predominantly on the dorsal aspect of her hands, anterior neck, and face, along with ill-defined hypopigmented to near-depigmented patches on her forearms and upper arms, involving approximately 20% of her body surface area... This case contributes to the limited literature on CDK4/6 inhibitor-induced pigmentary changes. It underscores the need for clinical awareness of this rare toxicity and demonstrates that switching agents within the same drug class may offer symptom resolution without compromising cancer treatment."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • HER-2 • PGR

An Exploratory Clinical Trial of CDK4/6 Inhibitor Dalpiciclib Combined with Aromatase Inhibitors as Neoadjuvant Therapy for Stage II-III HR-positive HER2-negative Breast Cancer (SABCS 2025) - "Participants receive dalpiciclib 150 mg/d (d1-21 every 28 days) + AIs (letrozole 2.5 mg/d, anastrozole 1 mg/d, or exemestane 25 mg/d); premenopausal women add ovarian suppression (goserelin/leuprolide). Conclusion Dalpiciclib combined with AIs demonstrates promising efficacy and manageable toxicity as neoadjuvant therapy for stage II-III HR+/HER2- breast cancer, offering a new chemotherapy-free option. Future research should focus on biomarker-guided patient selection, long-term outcomes assessment, and comparative trials with other neoadjuvant therapies, aiming to improve the treatment paradigm for HR+/HER2- breast cancer."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

PSMA uptake in glioblastoma: a diagnostic curveball in neuro-oncology (SNO 2025) - "In 2019, he developed nodal recurrence in retroperitoneal and bilateral iliac chain nodes, treated with lymphadenopathy, six cycles of Taxotere-based chemotherapy, and consolidative proton beam radiation (56.25 Gy/25 fractions)...PSA was undetectable on abiraterone/prednisone and leuprolide...He received standard-of-care treatment with radiation, temozolomide, and TTF device... This case illustrates the potential role of PSMA as a diagnostic tool, as it allows for easy identification of glioblastoma neovasculature, as demonstrated in our case report."

Brain Cancer • Genito-urinary Cancer • Glioblastoma • Glioma • High Grade Glioma • Prostate Cancer • Solid Tumor • FOLH1 • MGMT

POP-ELA: A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor

Primary high-grade urothelial carcinoma of the prostate combined with acinar adenocarcinoma: first rare case report and treatment experience summary. (PubMed, Front Oncol) - "Postoperatively, a surgery combined with targeted and immunotherapy regimen was initiated: leuprorelin + rezvilutamide for the acinar adenocarcinoma and disitamab vedotin + toripalimab for the urothelial carcinoma. The protocol of surgery combined with targeted and immunotherapy offers a new treatment strategy for this rare malignancy. This study provides valuable insights for clinical diagnosis and management."

Journal • Benign Prostatic Hyperplasia • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • Urothelial Cancer • GATA3

Does gonadotropin-releasing hormone analogue treatment alter body mass index in boys with central precocious puberty? (PubMed, Eur J Pediatr) - " Increase in BMI-SDS during the first year of GnRHa was only observed in NWs while OW and OBs maintained BMI-SDS. During adulthood, this increase of BMI-SDS in NWs was reversed while OBs exhibited a significant decrease. Lifestyle and diet programs should be implemented to NWs as well as OW and OBs boys with iCPP when initiating GnRHa treatment."

Journal • Endocrine Disorders • Genetic Disorders • Obesity

The effect of the magic glove technique on pain and anxiety in children during leuprolide injection: A quasi-experimental study. (PubMed, J Pediatr Nurs) - "The magic glove technique is a simple and low-cost method that can be integrated into pediatric nursing to reduce pain and anxiety during injections. Training nurses in this technique may promote child-centred, compassionate, and anxiety-reducing care."

Journal • Mental Retardation • Mood Disorders • Pain • Pediatrics • Psychiatry

Electroacupuncture for Refractory Chronic Pelvic Pain: A Case Report with 24-Month Follow-Up. (PubMed, Int J Womens Health) - "Despite treatment with leuprolide acetate and pregabalin, her pain persisted (NRS score of 7-8). EA may be a complementary and alternative therapy for CPP women, particularly when other treatments failed. Additionally, EA may offer potential long-term relief for CPP patients."

Journal • Gynecology • Musculoskeletal Pain • Pain

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: Fudan University | Recruiting ➔ Active, not recruiting

Enrollment closed • Non-Adenoid Cystic Carcinoma • Oncology • Salivary Gland Cancer • AR • HER-2

PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov) - P3 | N=504 | Completed | Sponsor: Alliance Foundation Trials, LLC. | Active, not recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Jun 2025

Trial completion • Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age. (PubMed, Eur J Cancer) - P3 | "Clinically meaningful improvements in MFS were observed following enzalutamide ± leuprolide in patients with hrBCR regardless of age. TRSAEs were more common in older patients but were low regardless of age. These findings should be interpreted in light of small subgroup sizes."

Journal • Retrospective data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • Urethral Cancer • Urology

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide monotherapy (enza mono): EMBARK post hoc analysis (EMUC 2025) - "Introduction & Objectives The phase 3 EMBARK trial demonstrated clinically meaningful improvement in metastasis-free survival and secondary efficacy endpoints with enza mono vs leuprolide alone. Pfizer's generative artificial intelligence (AI) assisted technology, MAIA (Medical Artificial Intelligence Assistant) was used in the production of this abstract. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication."

Clinical • Monotherapy • Retrospective data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide plus leuprolide (enza combo): EMBARK post hoc analysis (EMUC 2025) - "Pfizer's generative artificial intelligence (AI) assisted technology, MAIA (Medical Artificial Intelligence Assistant) was used in the production of this abstract. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication."

Clinical • Retrospective data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Recurrent Left-Sided Catamenial Pneumothorax in a Patient with Thoracic and Pelvic Endometriosis: A Multidisciplinary Approach (APSR 2025) - "She was initiated on hormonal suppression with leuprolide acetate (GnRH agonist) scheduled for Day 21 of her cycle (March 21, 2025)...A local case series (Cardinal Santos Medical Center, 2017–2018) reported only three CP cases, underscoring underdiagnosis in the Philippines. Awareness of prior pneumothorax temporally linked to menses is crucial for early recognition."

Clinical • Cardiovascular • Endometriosis • Gynecology • Pulmonary Disease • Respiratory Diseases • Ventricular Tachycardia • Women's Health

Clinical Effectiveness of Oral Relugolix in Advanced Prostate Cancer: A Structured Review of Current Primary Research. (PubMed, Cureus) - "In the HERO trial, Relugolix achieved castration-level testosterone (<50 ng/dL) in 96.7% of patients, outperforming Leuprolide (88.3%) in both speed (median = 4 days vs. 29 days) and magnitude of suppression...Additional studies confirmed its effectiveness when combined with radiotherapy in comparison with Degarelix...These advantages, along with oral administration, support its use as a viable alternative in clinical practice. Further long-term studies are warranted to confirm sustained outcomes and optimize treatment regimes."

Journal • Review • Cardiovascular • Genito-urinary Cancer • Oncology • Oral Cancer • Prostate Cancer • Solid Tumor